Abstract
Cancer stem cells (CSC) drive tumour progression and are implicated in relapse and resistance to conventional cancer therapies. Identification of differentially expressed genes by gene expression (GEP) profiling may help identify the differentially activated signalling pathways in cancer stem cells as opposed to bulk tumour cells which will provide new insights into cancer stem cell biology and aid in identification of novel therapeutic targets. Our study focused on the inhibition of CSC from cervical cancer cell lines by targeting insulin-like growth factor (IGF), which was identified by differential GEP. Targeted inhibition of IGF-1 by JB-1 trifluoroacetate (inhibitor of IGF) was carried out in SiHa, RSBS-14 and RSBS-43 cervical cancer derived cell lines. Effect of cisplatin was also evaluated. Inhibition of IGF-1 signalling was confirmed by demonstration of reduction in p-Akt levels. The cell biological effects of IGF-1 inhibition included an increase in G2M/S fraction, increased apoptosis and decreased invasive ability. JB-1 and cisplatin showed synergism. However, transcript levels of stemness and EMT markers showed variable levels following IGF inhibition. Overall, this proof-of-concept study has shown that IGF-1 is an attractive target for inhibition of CSC in invasive cervical cancer.
Similar content being viewed by others
Data Availability
The link for public data https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE120270
References
Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M et al (2015) Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 136:E359–E386
Dean M, Fojo T, Bates S (2005) Tumour stem cells and drug resistance. Nat Rev Cancer 5:275–284
Shim C, Zhang W, Rhee CH, Lee JH (1998) Profiling of differentially expressed genes in human primary cervical cancer by complementary DNA expression array. Clin Cancer Res 4:3045–3050
Cheng Q, Lau WM, Tay SK, Chew SH, Ho TH, Hui KM (2002) Identification and characterization of genes involved in the carcinogenesis of human squamous cell cervical carcinoma. Int J Cancer 98:419–426
Wong YF, Selvanayagam ZE, Wei N et al (2003) Expression genomics of cervical cancer: molecular classification and prediction of radiotherapy response by DNA microarray. Clin Cancer Res 9:5486–5492
Bachtiary B, Boutros PC, Pintilie M et al (2006) Gene expression profiling in cervical cancer: an exploration of intratumor heterogeneity. Clin Cancer Res 12:5632–5640
Javed S, Sharma BK, Sood S et al (2018) Significance of CD133 positive cells in four novel HPV-16 positive cervical cancer-derived cell lines and biopsies of invasive cervical cancer. BMC Cancer 18:357
Sunters A, Armstrong VJ, Zaman G et al (2010) Mechano-transduction in osteoblastic cells involves strain-regulated estrogen receptor alpha-mediated control of insulin-like growth factor (IGF) I receptor sensitivity to Ambient IGF, leading to phosphatidylinositol 3-kinase/AKT-dependent Wnt/LRP5 receptor-independent activation of beta-catenin signaling. J Biol Chem 285:8743–8758
Lin M, Ye M, Zhou J et al (2019) Recent Advances on the Molecular Mechanism of Cervical Carcinogenesis Based on Systems Biology Technologies. Comput Struct Biotechnol J 17:241–250
Rao Q-X, Yao T-T, Zhang B-Z et al (2012) Expression and Functional Role of ALDH1 in Cervical Carcinoma Cells. Asian Pac J Cancer Prev 13:1325–1331
Lopez J, Poitevin A, Mendoza-Martinez V, Perez-Plasencia C, Garcia-Carranca A (2012) Cancer-initiating cells derived from established cervical cell lines exhibit stem-cell markers and increased radioresistance. BMC Cancer 12:48
Shen MR, Hsu YM, Hsu KF, Chen YF, Tang MJ, Chou CY (2006) Insulin-like growth factor 1 is a potent stimulator of cervical cancer cell invasiveness and proliferation that is modulated by alphavbeta3 integrin signaling. Carcinogenesis 27:962–971
Steller MA, Delgado CH, Bartels CJ, Woodworth CD, Zou Z (1996) Overexpression of the insulin-like growth factor-1 receptor and autocrine stimulation in human cervical cancer cells. Cancer Res 56:1761–1765
Prager D, Li HL, Asa S, Melmed S (1994) Dominant negative inhibition of tumorigenesis in vivo by human insulin-like growth factor I receptor mutant. Proc Natl Acad Sci U S A 91:2181–2185
Huang YF, Shen MR, Hsu KF, Cheng YM, Chou CY (2008) Clinical implications of insulin-like growth factor 1 system in early-stage cervical cancer. Br J Cancer 99:1096–1102
Nakamura K, Hongo A, Kodama J, Miyagi Y, Yoshinouchi M, Kudo T (2000) Down-regulation of the insulin-like growth factor I receptor by antisense RNA can reverse the transformed phenotype of human cervical cancer cell lines. Cancer Res 60:760–765
Somri-Gannam L, Meisel-Sharon S, Hantisteanu S, et al. IGF1R Axis Inhibition Restores Dendritic Cell Antitumor Response in Ovarian Cancer. Transl Oncol. 2020; 100790.
Chen J, Zeng J, Xin M, Huang W, Chen X (2011) Formononetin induces cell cycle arrest of human breast cancer cells via IGF1/PI3K/Akt pathways in vitro and in vivo. Horm Metab Res 43:681–686
Singh B, Smith JA, Axelrod DM et al (2014) Insulin-like growth factor-I inhibition with pasireotide decreases cell proliferation and increases apoptosis in pre-malignant lesions of the breast: a phase 1 proof of principle trial. Breast Cancer Res 16:463
Shukla S, Maclennan GT, Hartman DJ, Fu P, Resnick MI, Gupta S (2007) Activation of PI3K-Akt signaling pathway promotes prostate cancer cell invasion. Int J Cancer 121:1424–1432
Zhou P, Li B, Liu F et al (2017) The epithelial to mesenchymal transition (EMT) and cancer stem cells: implication for treatment resistance in pancreatic cancer. Mol Cancer 16:52
Sharma A, De R, Javed S, Srinivasan R, Pal A, Bhattacharyya S. Sonic hedgehog pathway activation regulates cervical cancer stem cell characteristics during epithelial to mesenchymal transition. J Cell Physiol. 2019;4.
Denduluri SK, Idowu O, Wang Z et al (2015) Insulin-like growth factor (IGF) signaling in tumorigenesis and the development of cancer drug resistance. Genes Dis 2:13–25
King H, Aleksic T, Haluska P, Macaulay VM (2014) Can we unlock the potential of IGF-1R inhibition in cancer therapy? Cancer Treat Rev 40:1096–1105
Funding
Department of Science and Technology, Govt. of India, grant reference no.- DST No: D.O. No.-SR/SO/HS-0166/2010; PGI Intramural Research Scheme No. 71/5-EDU/12/1363; Shifa Javed was supported by Indian Council of Medical Research Junior Research Fellowships ICMR-JRF-2012/HRD-139(10056).
Author information
Authors and Affiliations
Contributions
SJ conducted all experiments and manuscript writing; SB, RB and RS conceived the project, designed the study. All authors read and approved the final manuscript.
Corresponding author
Ethics declarations
Conflict of interest
The authors listed have no conflicts of interest.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Electronic supplementary material
Below is the link to the electronic supplementary material.
Rights and permissions
About this article
Cite this article
Javed, S., Bhattacharyya, S., Bagga, R. et al. Insulin growth factor-1 pathway in cervical carcinoma cancer stem cells. Mol Cell Biochem 473, 51–62 (2020). https://doi.org/10.1007/s11010-020-03807-6
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11010-020-03807-6